Alkermes – A global biopharmaceutical company

About Us

About Alkermes

Our Company Message From the CEO Locations

Leadership

Management Team Board of Directors

Collaborations

Strategic Partners

Products

Products Overview

United States

ARISTADA^® VIVITROL^® U.S. Products Using Alkermes Technologies Wholesaler and Purchasing Information

European Union

EU Products Using Alkermes Technologies

Research & Development

R&D Overview Our R&D Approach Pipeline Technology Platforms Manufacturing

Other Information

Clinical Trials Expanded Access

Responsibility

Alkermes Corporate Giving Investigator Initiated Trials Educational Grants Patient Engagement Support ALKERMES Inspiration Grants™

Investors

Corporate Overview Press Releases Investor Events Stock Information SEC Filings Annual Reports

Financials

Snapshot Trading Statistics

Other Information

Email Alerts

News & Events

Press Releases Media Kit

Careers

Working Together Our Core Values Total Rewards Meet Our Employees Recruiting Agencies Equal Opportunity Employer

Job Opportunities

Jobs Overview Field Sales Roles All Available Roles

Latest News

Alkermes to Host Conference Call to Discuss Second Quarter 2017 Financial Results Read More
Alkermes Announces Positive Preliminary Topline Results From Phase 3 Antipsychotic Efficacy Study of ALKS 3831 for Treatment of Schizophrenia Read More
Alkermes Announces Initiation of Study 217 for ALKS 5461 for Treatment of Major Depressive Disorder Read More